##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 Form 10-QSB
  þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended June 30, 2006
 o
    
    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE
ACT
 For the transition period from  to
 Commission file number 0-12627
 MEDICAL DISCOVERIES, INC.
  Utah
    
    87-0407858(State or other jurisdiction of
incorporation or organization)
    
    (I.R.S. Employer
Identification No.)
 1388 S. Foothill Drive, #266, Salt Lake City, Utah 84108
   (Issuers telephone number, including area code)
  (Former name, former address and former fiscal year, if changed since last report)
 þ o
 o þ
   o þ




---



##### 



PART IFINANCIAL INFORMATIONITEM 1. FINANCIAL STATEMENTS
    
    
    3ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
    
    
    11ITEM 3. CONTROLS AND PROCEDURES
    
    
    15PART IIOTHER INFORMATIONITEM 6. EXHIBITS
    
    
    16SIGNATURES
    
    
    18INDEX TO EXHIBITSEXHIBIT 31.1EXHIBIT 31.2EXHIBIT 32.1EXHIBIT 32.2
  -2-




---



##### Table of Contents



PART I
 
 FINANCIAL INFORMATION
 
 ITEM 1. FINANCIAL STATEMENTS
      -3-




---



##### Table of Contents



MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES
 June 30,
    
    
    December 31,2006
    
    
    2005ASSETSCURRENT ASSETSCash
    
    $
    106,123
    
    
    $
    654,438Total Current Assets
    
    
    106,123
    
    
    
    654,438Note receivable
    
    
    319,475
    
    
    
    296,050Property and Equipment, Net
    
    
    71,164
    
    
    
    80,635TOTAL ASSETS
    
    $
    496,762
    
    
    $
    1,031,123LIABILITIES AND STOCKHOLDERS DEFICITCURRENT LIABILITIESAccounts payable
    
    $
    2,151,935
    
    
    $
    2,608,783Accrued interest payable
    
    
    252,664
    
    
    
    237,836Notes payable
    
    
    56,000
    
    
    
    56,000Convertible notes payable
    
    
    193,200
    
    
    
    193,200Research and development obligation
    
    
    638,950
    
    
    
    592,100Deferred revenue
    
    
    192,825
    
    
    
    Financial instrument
    
    
    1,979,516
    
    
    
    2,859,596Total Current Liabilities
    
    
    5,465,090
    
    
    
    6,547,515NOTE PAYABLE
    
    
    90,000
    
    
    
    TOTAL LIABILITIES
    
    
    5,555,090
    
    
    
    6,547,515STOCKHOLDERS DEFICITPreferred Stock  undesignated, Series A, convertible; no par value; 50,000 shares
authorized; 34,420 and 42,000 shares issued and outstanding, respectively;
(aggregate liquidation preference of $3,442,000 and $4,200,000, respectively)
    
    
    514,612
    
    
    
    523,334Common stock, no par value; 250,000,000 shares authorized; 117,922,148 and
107,679,724 shares issued and outstanding, respectively
    
    
    15,220,617
    
    
    
    15,211,895Additional paid  in capital
    
    
    1,056,020
    
    
    
    988,670Deficit accumulated prior to the development stage
    
    
    (1,399,577
    )
    
    
    (1,399,577
    )Deficit accumulated during the development stage
    
    
    (20,450,000
    )
    
    
    (20,840,714
    )Total Stockholders Deficit
    
    
    (5,058,328
    )
    
    
    (5,516,392
    )TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT
    
    $
    496,762
    
    
    $
    1,031,123
  -4-




---



##### Table of Contents



MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES
 From Inceptionof theDevelopmentFor the Three
    
    
    For the Six
    
    
    Stage onMonths Ended
    
    
    Months Ended
    
    
    November 20, 1991June 30,
    
    
    June 30,
    
    
    Through June 30,2006
    
    
    2005
    
    
    2006
    
    
    2005
    
    
    2006REVENUES
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    157,044COST OF GOODS SOLD
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    14,564GROSS PROFIT
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    142,480OPERATING EXPENSESGeneral and administrative
    
    
    385,946
    
    
    
    636,325
    
    
    
    731,466
    
    
    
    888,321
    
    
    
    17,786,463Research and development
    
    
    234,659
    
    
    
    118,520
    
    
    
    327,242
    
    
    
    1,670,506
    
    
    
    6,048,441Inventory write-down
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    96,859Impairment loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    9,709License fees
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    1,001,500Total Expenses
    
    
    620,605
    
    
    
    754,845
    
    
    
    1,058,708
    
    
    
    2,558,827
    
    
    
    24,942,972LOSS FROM OPERATIONS
    
    
    (620,605
    )
    
    
    (754,845
    )
    
    
    (1,058,708
    )
    
    
    (2,558,827
    )
    
    
    (24,800,492
    )OTHER INCOME (EXPENSES)Unrealized gain on financial instrument
    
    
    1,999,857
    
    
    
    2,133,177
    
    
    
    880,080
    
    
    
    1,990,915
    
    
    
    3,180,271Interest income
    
    
    565
    
    
    
    9,346
    
    
    
    1,776
    
    
    
    14,910
    
    
    
    57,074Interest expense
    
    
    (7,472
    )
    
    
    (7,237
    )
    
    
    (14,844
    )
    
    
    (23,135
    )
    
    
    (1,170,545
    )Foreign currency transaction gain (loss)
    
    
    (16,000
    )
    
    
    40,900
    
    
    
    (23,425
    )
    
    
    60,800
    
    
    
    33,055Gain on debt restructuring
    
    
    605,052
    
    
    
    196,353
    
    
    
    605,052
    
    
    
    196,353
    
    
    
    2,036,941Other income
    
    
    783
    
    
    
    
    
    
    
    783
    
    
    
    
    
    
    
    905,895Total Other Income
    
    
    2,582,785
    
    
    
    2,372,539
    
    
    
    1,449,422
    
    
    
    2,239,843
    
    
    
    5,042,691NET INCOME (LOSS)
    
    
    1,962,180
    
    
    
    1,617,694
    
    
    
    390,714
    
    
    
    (318,984
    )
    
    
    (19,757,801
    )Preferred stock dividend from
beneficial conversion feature
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (692,199
    )NET INCOME (LOSS) APPLICABLE TO
COMMON SHAREHOLDERS
    
    $
    1,962,180
    
    
    $
    1,617,694
    
    
    $
    390,714
    
    
    $
    (318,984
    )
    
    $
    (20,450,000
    )BASIC EARNINGS (LOSS) PER SHARE
    
    $
    0.02
    
    
    $
    0.02
    
    
    $
    
    
    
    $
    DILUTED EARNINGS (LOSS) PER SHARE
    
    $
    0.01
    
    
    $
    0.01
    
    
    $
    
    
    
    $
    
  -5-




---



##### Table of Contents



MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES
 From InceptionFor the Six
    
    
    of theMonths Ended
    
    
    Development StageJune 30,
    
    
    on November 20, 19912006
    
    
    2005
    
    
    Through June 30, 2006CASH FLOWS FROM OPERATING ACTIVITIESNet Income (Loss)
    
    $
    390,714
    
    
    $
    (318,984
    )
    
    $
    (19,757,801
    )Adjustments to reconcile net loss to net cash used by operating activities:Foreign currency transaction (gain) loss
    
    
    23,425
    
    
    
    (60,800
    )
    
    
    (33,055
    )Gain on debt restructuring
    
    
    (605,052
    )
    
    
    (196,353
    )
    
    
    (2,036,941
    )Common stock issued for services, expenses, and litigation
    
    
    
    
    
    
    18,750
    
    
    
    4,267,717Commitment for research and development obligation
    
    
    
    
    
    
    665,700
    
    
    
    665,700Depreciation
    
    
    9,471
    
    
    
    870
    
    
    
    118,257Reduction of escrow receivable from research and development
    
    
    
    
    
    
    
    
    
    
    272,700Unrealized gain on financial instrument
    
    
    (880,080
    )
    
    
    (1,990,915
    )
    
    
    (3,180,271
    )Stock options and warrants granted for services
    
    
    67,350
    
    
    
    
    
    
    
    4,878,603Reduction of legal costs
    
    
    
    
    
    
    
    
    
    
    (130,000
    )Write-off of subscriptions receivable
    
    
    
    
    
    
    
    
    
    
    112,500Impairment of loss on assets
    
    
    
    
    
    
    
    
    
    
    9,709Loss on disposal of equipment
    
    
    
    
    
    
    
    
    
    
    30,364Write-off of accounts receivable
    
    
    
    
    
    
    
    
    
    
    245,065Note payable issued for litigation
    
    
    
    
    
    
    
    
    
    
    385,000Changes in operating assets and liabilitiesIncrease in accounts receivable
    
    
    
    
    
    
    
    
    
    
    (7,529
    )Increase in accounts payable
    
    
    238,204
    
    
    
    162,889
    
    
    
    2,702,390Increase in accrued expenses
    
    
    14,828
    
    
    
    23,134
    
    
    
    652,747Increase in deferred revenue
    
    
    192,825
    
    
    
    
    
    
    
    192,825Net Cash Used by Operating Activities
    
    
    (548,315
    )
    
    
    (1,695,709
    )
    
    
    (10,612,020
    )CASH FLOWS FROM INVESTING ACTIVITIESIncrease in deposits
    
    
    
    
    
    
    
    
    
    
    (51,100
    )Purchase of equipment
    
    
    
    
    
    
    (68,491
    )
    
    
    (221,334
    )Issuance of notes receivable
    
    
    
    
    
    
    
    
    
    
    (313,170
    )Payments received on notes receivable
    
    
    
    
    
    
    
    
    
    
    130,000Net Cash Used by Investing Activities
    
    
    
    
    
    
    (68,491
    )
    
    
    (455,604
    )CASH FLOWS FROM FINANCING ACTIVITIESIssuance of common stock, preferred stock and warrants for cash
    
    
    
    
    
    
    3,033,000
    
    
    
    10,033,845Contributed equity
    
    
    
    
    
    
    
    
    
    
    131,374Proceeds from notes payable
    
    
    
    
    
    
    
    
    
    
    1,336,613Payments on notes payable
    
    
    
    
    
    
    (300,000
    )
    
    
    (801,287
    )Proceeds from convertible notes payable
    
    
    
    
    
    
    
    
    
    
    571,702Payments on convertible notes payable
    
    
    
    
    
    
    
    
    
    
    (98,500
    )Net Cash Provided by Financing Activities
    
    
    
    
    
    
    2,733,000
    
    
    
    11,173,747NET INCREASE (DECREASE) IN CASH
    
    
    (548,315
    )
    
    
    968,800
    
    
    
    106,123CASH AT BEGINNING OF PERIOD
    
    
    654,438
    
    
    
    1,455,397
    
    
    
    CASH AT END OF PERIOD
    
    $
    106,123
    
    
    $
    2,424,197
    
    
    $
    106,123
  -6-




---



##### Table of Contents



MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES
 For the SixMonths EndedJune 30,2006
    
    2005SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATIONInitial valuation of financial instrument
    
    $
    
    
    
    $
    6,279,829Conversion of preferred stock to common stock
    
    $
    8,722
    
    
    $
    
  -7-




---



##### Table of Contents



MEDICAL DISCOVERIES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Unaudited Condensed Consolidated Financial Statements
 Note 1  Basis of Presentation
 Unaudited Interim Consolidated Financial Statements
  Earnings (Loss) Per Common Share
  For the Three Months
    
    
    For the Six MonthsEnded June 30,
    
    
    Ended June 30,2006
    
    
    2005
    
    
    2006
    
    
    2005Net income (loss)
    
    $
    1,962,180
    
    
    $
    1,617,694
    
    
    $
    390,714
    
    
    $
    (318,984
    )Basic weighted-average common shares outstanding
    
    
    111,255,481
    
    
    
    107,580,033
    
    
    
    109,576,693
    
    
    
    107,043,413Convertible notes
    
    
    128,671
    
    
    
    128,671
    
    
    
    128,671
    
    
    
    Convertible preferred stock
    
    
    48,478,873
    
    
    
    57,776,847
    
    
    
    48,478,873
    
    
    
    Warrants
    
    
    535,829
    
    
    
    767,936
    
    
    
    679,786
    
    
    
    Stock options
    
    
    14,316,063
    
    
    
    16,289,969
    
    
    
    14,587,548
    
    
    
    Diluted weighted-average common shares outstanding
    
    
    174,714,917
    
    
    
    182,543,456
    
    
    
    173,451,571
    
    
    
    107,043,413Basic net earnings (loss) per common share
    
    $
    0.02
    
    
    $
    0.02
    
    
    $
    
    
    
    $
    Diluted net earnings (loss) per common share
    
    $
    0.01
    
    
    $
    0.01
    
    
    $
    
    
    
    $
    
  For the Three Months
    
    For the Six MonthsEnded June 30,
    
    Ended June 30,2006
    
    2005
    
    2006
    
    2005Convertible notes
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    128,671Convertible preferred stock
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    59,786,477Warrants
    
    
    38,567,161
    
    
    
    38,567,161
    
    
    
    38,567,161
    
    
    
    40,923,861Options
    
    
    2,233,000
    
    
    
    2,233,000
    
    
    
    1,733,000
    
    
    
    19,483,00040,800,161
    
    
    
    40,800,161
    
    
    
    40,300,161
    
    
    
    120,322,009
 -8-




---



##### Table of Contents



Stock Based Compensation
    Note 2  Going Concern Considerations
  Note 3  Preferred Stock, Financial Instrument, and Options
    -9-




---



##### Table of Contents



Note 4  Related Party Transactions
      
 
 Note 5  Other Significant Transactions
 SaveCream Asset Purchase
     
  
 -10-




---



##### Table of Contents



Debt Restructuring
  Licensing Agreement
   
 ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
   Overview
   -11-




---



##### Table of Contents



Recent Events
   Cystic Fibrosis IND.
  Results of Operations
 Revenues and Gross Profit 
 -12-




---



##### Table of Contents



Operating Expenses and Operating Income or Loss
  Other Income/Expense and Net Loss 
  Future Expectations
 -13-




---



##### Table of Contents



Liquidity and Capital Resources
   Off-Balance Sheet Arrangements
  Cautionary Statement for Forward Looking Information
    -14-




---



##### Table of Contents



ITEM 3. CONTROLS AND PROCEDURES
   -15-




---



##### Table of Contents



PART II
 
 OTHER INFORMATION
 
 ITEM 6. EXHIBITS
  Number
    
    Exhibit2.1
    
    Sale and Purchase Agreement between Attorney
Hinnerk-Joachim Müller as liquidator of
Savetherapeutics AG i.L. and Medical
Discoveries, Inc. regarding the purchase of the
essential assets of Savetherapeutics AG i.L.
(filed as Exhibit 2.1 to the Companys Annual
Report on Form 10-KSB for the fiscal year ended
December 31, 2004, and incorporated herein by
reference).3.1
    
    Amended and Restated Articles of Incorporation
of the Company (filed as Exhibit 3.1 to the
Companys Annual Report on Form 10-KSB for the
fiscal year ended December 31, 1994, and
incorporated herein by reference).3.2
    
    Amended Bylaws of the Company (filed as Exhibit
3.2 to the Companys Annual Report on Form
10-KSB for the fiscal year ended December 31,
1994, and incorporated herein by reference).4.1
    
    Registration Rights Agreement dated October 18,
2004 among Monarch Pointe Fund, Ltd., Mercator
Advisory Group, LLC and Medical Discoveries,
Inc. (filed as Exhibit 4.1 to the
Companys Annual Report on Form 10-KSB for the
fiscal year ended December 31, 2004, and
incorporated herein by reference).4.2
    
    Registration Rights Agreement dated December 3,
2004 among Mercator Momentum Fund, LP, Mercator
Momentum Fund III, LP, Mercator Advisory Group,
LLC and Medical Discoveries, Inc.
(filed as Exhibit 4.2 to the Companys
Annual Report on Form 10-KSB for the fiscal year
ended December 31, 2004, and incorporated herein
by reference).4.3
    
    Certificate of Designations of Preferences and
Rights of Series A Convertible Preferred Stock
of Medical Discoveries, Inc. (filed as Exhibit
4.1 to Registration Statement No. 333-121635
filed on Form SB-2 on December 23, 2004, and
incorporated herein by reference).4.4
    
    Amendment to Certificate of Designations of
Preferences and Rights of Series A Convertible
Preferred Stock of Medical Discoveries, Inc.
(filed as Exhibit 4.2 to Registration Statement
No. 333-121635 filed on Form SB-2 on December
23, 2004, and incorporated herein by reference).10.1
    
    2002 Stock Incentive Plan adopted by the Board
of Directors as of July 11, 2002 (filed as
Exhibit 10.5 to the Companys Quarterly Report
on Form 10-QSB for the quarter ended June 30,
2002, and incorporated herein by reference).10.2
    
    Subscription Agreement dated October 18, 2004
among Monarch Pointe Fund, Ltd., Mercator
Advisory Group, LLC, and Medical Discoveries,
Inc. (filed as Exhibit 10.2 to Amendment No. 2
to Registration Statement No. 333-121635 filed
on form SB-2 on June 2, 2005, and incorporated
herein by reference).10.3
    
    Subscription Agreement dated December 3, 2004
among Mercator Momentum Fund, LP, Mercator
Momentum Fund III, LP, Mercator Advisory Group,
LLC, and Medical Discoveries, Inc. (filed as
Exhibit 10.3 to Amendment No. 2 to Registration
Statement No. 333-121635 filed on form SB-2 on
June 2, 2005, and incorporated herein by
reference).
 -16-




---



##### Table of Contents



Number
    
    Exhibit10.4
    
    Employment Agreement dated March 1, 2005 between
Medical Discoveries, Inc. and Judy M. Robinett.
(filed as Exhibit 10.4 to Amendment No. 3 to
Registration Statement No. 333-121635 filed on
Form SB-2 on October 13, 2005, and incorporated
herein by reference).10.5
    
    Definitive Master Agreement, dated as of July
29, 2006, by and between MDI Oncology, Inc. and
Eucodis Forschungs und Entwicklungs GmbH (filed
as Exhibit 10.1 to the Companys Current Report
on Form 8-K filed August 3, 2006, and
incorporated herein by reference).31.1
    
    Rule 13a-14(a) Certification, as adopted
pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.*31.2
    
    Rule 13a-14(a) Certification, as adopted
pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.*32.1
    
    Certification pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.*32.2
    
    Certification pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.*
 
 *
    
    Filed herewith. -17-




---



##### Table of Contents



SIGNATURES
  MEDICAL DISCOVERIES, INC./S/ JUDY M. ROBINETT

Judy M. RobinettPresident and Chief Executive OfficerDate: August 14, 2006
 -18-




---



##### Table of Contents



INDEX TO EXHIBITS
 Number
    
    Exhibit2.1
    
    Sale and Purchase Agreement between Attorney
Hinnerk-Joachim Müller as liquidator of
Savetherapeutics AG i.L. and Medical
Discoveries, Inc. regarding the purchase of the
essential assets of Savetherapeutics AG i.L.
(filed as Exhibit 2.1 to the Companys Annual
Report on Form 10-KSB for the fiscal year ended
December 31, 2004, and incorporated herein by
reference).3.1
    
    Amended and Restated Articles of Incorporation
of the Company (filed as Exhibit 3.1 to the
Companys Annual Report on Form 10-KSB for the
fiscal year ended December 31, 1994, and
incorporated herein by reference).3.2
    
    Amended Bylaws of the Company (filed as Exhibit
3.2 to the Companys Annual Report on Form
10-KSB for the fiscal year ended December 31,
1994, and incorporated herein by reference).4.1
    
    Registration Rights Agreement dated October 18,
2004 among Monarch Pointe Fund, Ltd., Mercator
Advisory Group, LLC and Medical Discoveries,
Inc. (filed as Exhibit 4.1 to the
Companys Annual Report on Form 10-KSB for the
fiscal year ended December 31, 2004, and
incorporated herein by reference).4.2
    
    Registration Rights Agreement dated December 3,
2004 among Mercator Momentum Fund, LP, Mercator
Momentum Fund III, LP, Mercator Advisory Group,
LLC and Medical Discoveries, Inc.
(filed as Exhibit 4.2 to the Companys
Annual Report on Form 10-KSB for the fiscal year
ended December 31, 2004, and incorporated herein
by reference).4.3
    
    Certificate of Designations of Preferences and
Rights of Series A Convertible Preferred Stock
of Medical Discoveries, Inc. (filed as Exhibit
4.1 to Registration Statement No. 333-121635
filed on Form SB-2 on December 23, 2004, and
incorporated herein by reference).4.4
    
    Amendment to Certificate of Designations of
Preferences and Rights of Series A Convertible
Preferred Stock of Medical Discoveries, Inc.
(filed as Exhibit 4.2 to Registration Statement
No. 333-121635 filed on Form SB-2 on December
23, 2004, and incorporated herein by reference).10.1
    
    2002 Stock Incentive Plan adopted by the Board
of Directors as of July 11, 2002 (filed as
Exhibit 10.5 to the Companys Quarterly Report
on Form 10-QSB for the quarter ended June 30,
2002, and incorporated herein by reference).10.2
    
    Subscription Agreement dated October 18, 2004
among Monarch Pointe Fund, Ltd., Mercator
Advisory Group, LLC, and Medical Discoveries,
Inc. (filed as Exhibit 10.2 to Amendment No. 2
to Registration Statement No. 333-121635 filed
on form SB-2 on June 2, 2005, and incorporated
herein by reference).10.3
    
    Subscription Agreement dated December 3, 2004
among Mercator Momentum Fund, LP, Mercator
Momentum Fund III, LP, Mercator Advisory Group,
LLC, and Medical Discoveries, Inc. (filed as
Exhibit 10.3 to Amendment No. 2 to Registration
Statement No. 333-121635 filed on form SB-2 on
June 2, 2005, and incorporated herein by
reference).10.4
    
    Employment Agreement dated March 1, 2005 between
Medical Discoveries, Inc. and Judy M. Robinett.
(filed as Exhibit 10.4 to Amendment No. 3 to
Registration Statement No. 333-121635 filed on
Form SB-2 on October 13, 2005, and incorporated
herein by reference).10.5
    
    Definitive Master Agreement, dated as of July
29, 2006, by and between MDI Oncology, Inc. and
Eucodis Forschungs und Entwicklungs GmbH (filed
as Exhibit 10.1 to the Companys Current Report
on Form 8-K filed August 3, 2006, and
incorporated herein by reference).




---



##### Table of Contents



Number
    
    Exhibit31.1
    
    Rule 13a-14(a) Certification, as adopted
pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.*31.2
    
    Rule 13a-14(a) Certification, as adopted
pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.*32.1
    
    Certification pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.*32.2
    
    Certification pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.*
 
 *
    
    Filed herewith.